EpiCapture Limited is a spinout from University College Dublin focusing on developing accurate and non-invasive liquid tests to detect aggressive cancer. The company was founded in 2021 by Dr. Antoinette Perry and Edward Simons.

Mission

We are focused on improving lives through the development of non-invasive liquid biopsy tests. Liquid biopsies, such as urine, are liquid gold for accurate and early cancer detection. They provide a seamless solution to enable informed decision making when considering costly, invasive and risky surgical procedures. They can be repeated frequently with minimal discomfort, providing up-to-date peace of mind for patients and clinicians alike.

EpiCapture Limited is the commercialisation vehicle for translational research carried out by Associate Professor Antoinette Perry, Co-Director of the Cancer Biology and Therapeutics Lab in University College Dublin (UCD), Ireland. Professor Perry’s research is focused on the discovery and development of liquid biopsy tests for early detection and prognostic assessment of cancer. A urine test to detect aggressive prostate cancer  (EpiCapture-prostate) is the first product to transition to commercialisation. Research has also commenced on the development of a test for ovarian cancer (EpiCapture-ovarian).

Our mission is to make a patient’s diagnostic journey as easy and straightforward as possible. We are passionate about translating scientific discovery into innovative, patient-centric diagnostic solutions for early cancer detection.